Litcius/Paper detail

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Yelena Y. Janjigian, S-E. Al-Batran, Zev A. Wainberg, Eric Van Cutsem, Daniela Molena, Kei Muro, Woo Jin Hyung, Lucjan Wyrwicz, D-Y. Oh, Takeshi Omori, Markus Moehler, Marcelo Garrido, Sofia Oliveira, Moïshe Liberman, Victor Castro Oliden, Mehmet Bilici, John F. Kurland, Ioannis Xynos, Helen Mann, Josep Tabernero

2023Annals of Oncology82 citationsDOI

Topics & Concepts

MedicineDocetaxelOxaliplatinInternal medicineFluorouracilPhases of clinical researchCancerOncologyGastroenterologyChemotherapyColorectal cancerGastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentLung Cancer Diagnosis and Treatment
LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study | Litcius